Investors in Swiss pharmaceuticals firm Roche (RHHBY) were left nursing a headache today as its stock dropped on plans to ...

Shares of Puma Biotechnology PBYI have rallied 35.3% in the past six months against the industry’s decline of 9.2%. The ...

Roche RHHBY announced that it has entered into an ... Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous ...

Per a licensing deal signed in 2019, RHHBY has exclusive rights to launch ... During this timeframe, the stock has also underperformed the broader Medical sector and the S&P 500 Index.

RHHBY buys rights to obesity candidate from Zealand ... Wealth host Brad Smith discusses some of Wednesday's trending stocks. Novo Nordisk (NVO) stock is sinking after European drugmaker Roche ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this deal is a win-win for RHHBY & ZLDPF.

that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy. Price Action: RHHBY stock closed at $41.74 on Friday.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.